Cure My Disease

Don't miss your cure!

 Log in / Sign up

One visit, one cure: AI and smart pillboxes take on hepatitis c

NCT ID NCT07793643

Cure Sponsor: Patrick Grace Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether people with hepatitis C can be tested and treated in a single emergency department visit. Adults who test positive will receive antiviral medication before leaving, along with a smart pillbox, an AI virtual agent, and community health worker support to help them stick to the treatment. Researchers will track how well participants take their medication and whether the infection is cured four weeks after finishing treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sofosbuvir and velpatasvir (Epclusa)
What this could lead to
If this works, it could show that emergency departments can cure hepatitis C in one visit, making treatment faster and more accessible for many people.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. Some people may not finish treatment or may have side effects from the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 22-65 years old, presenting to the Emergency Department (ED) who are undergoing antibody testing as part of universal screening * Patients to be discharged from the ED or ED Observational units Exclusion Criteria: * Capacity to Consent * Emergency Severity Index (ESI) Level one (high acuity patients) * Known noninvasive serologic tests above proprietary cutoffs indicating cirrhosis (example - FibroSure, Enhanced Liver Fibrosis Test, etc.) * Known clinical evidence of cirrhosis (egliver nodularity and/or splenomegaly on imaging, platelet count \<150,000/m3, etc.) * Known prior liver biopsy showing cirrhosis •Pregnancy * Known or suspected Hepatocellular carcinoma * Followed by hospice or transplant, have a life expectancy \< 1 year * Chronic Kidney Disease (CKD) or on dialysis * Allergy to study medications * Patients admitted to the hospital

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C (HCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C (HCV)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Kentucky

    Lexington, Kentucky, 40506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.